Trial data comparison: difference between revisions
Diff·revision 5 → 6·20:58, 20 Jan 2025
Difference between revision 5 and revision 6 of Trial data comparison. 3 lines changed; the page grew by 503 bytes.
| Revision 5 — 17:51, 11 Jan 2025 CiteBot (talk) bot: normalise citation format 1,546 bytes ±0 | Revision 6 — 20:58, 20 Jan 2025 DiffWatchDov (talk) add the medical-disclaimer cross-link to the tool pages 2,049 bytes +503 | ||
|---|---|---|---|
| 9 | The table is easy to misread in one specific way, and the article exists partly to prevent it. '''Two figures from two trials are not a comparison of two drugs.''' Trial populations differ in baseline weight, glycaemic status, diabetes duration, background therapy and geography; durations differ; and the statistical estimand used to summarise a weight-change endpoint differs between publications and sometimes within a single one.{{r|ich9r1}} A larger number in this table means a larger result in that trial, and nothing more. | 9 | The table is easy to misread in one specific way, and the article exists partly to prevent it. '''Two figures from two trials are not a comparison of two drugs.''' Trial populations differ in baseline weight, glycaemic status, diabetes duration, background therapy and geography; durations differ; and the statistical estimand used to summarise a weight-change endpoint differs between publications and sometimes within a single one.{{r|ich9r1}} A larger number in this table means a larger result in that trial, and nothing more. |
| 10 | 10 | ||
| + | 11 | Where a genuine head-to-head randomised comparison exists — SURPASS-2 compared tirzepatide with semaglutide 1 mg directly — the comparator column says so, and only those rows support a statement that one agent outperformed another.{{r|surpass2}} | |
| + | 12 | ||
| 11 | == The comparison == | 13 | == The comparison == |
| 12 | Filter by compound, trial programme or endpoint type. The bar is drawn to the magnitude of the primary result and is scaled within its endpoint type only. | 14 | Filter by compound, trial programme or endpoint type. The bar is drawn to the magnitude of the primary result and is scaled within its endpoint type only. |
| ⋮ | ⋮ | ||
| 15 | {{reflist}} | 17 | {{reflist}} |
| 16 | <ref name="ich9r1">International Council for Harmonisation, ''E9(R1): Addendum on Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> | 18 | <ref name="ich9r1">International Council for Harmonisation, ''E9(R1): Addendum on Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> |
| + | 19 | <ref name="surpass2">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). DOI:10.1056/NEJMoa2107519. PMID 34170647.</ref> | |
| 17 | 20 | ||
| 18 | {{DEFAULTSORT:Trial data comparison}} | 21 | {{DEFAULTSORT:Trial data comparison}} |